Should Pharma Focus on New Chemical Entities to Avoid Patent Challenge?

As part of the new Pharma Leaders Today series, Philip C. Strassburger, V.P., Intellectual Property Counsel at Purdue Pharma, spoke to Andrea Charles from Pharma IQ, about what trends he is currently seeing in pharmaceutical and biotech patents and overcoming the challenges faced when organising and managing a foreign patent litigation strategy. Strassburger aslo shares his insights on how changing patent settlements are imapcting on Pharma and what it takes to be a leader in Pharma.

Philip Strassburger joined Purdue Pharma L.P. in 1999. Before joining Purdue he served as Senior Patent Counsel at Pfizer, Inc., and as an associate at the law firms of Hedman Gibson and Bryan Cave in New York. Prior to his legal career, Mr. Strassburger practiced as a Chemical Process Engineer in The Netherlands.

He was named Vice President, Intellectual Property Counsel of Purdue in 2001. Mr. Strassburger has worldwide responsibility for patent litigation, patent prosecution, data exclusivity, trademarks, and copyrights. In that capacity he has negotiated numerous licenses and patent settlements throughout the world. In the United States he is also responsible for antitrust, transactional and regulatory law.

Mr. Strassburger received his B.S. degree in Chemical Engineering and his B.A. in Philosophy from Tufts University, and a Juris Doctorate degree from the University of Connecticut. He is admitted to practice in the State of New York and the State of Connecticut, as well as the U.S. Patent and Trademark Office. He is a frequent speaker at patent, regulatory, and antitrust conferences.